Clinical Study, Opened, of Cutaneous Acceptability of a Topic Product in Normal Conditions of Use

NCT ID: NCT02695706

Last Updated: 2016-03-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The measured product in this research is a product for topical use, Laboratoires Mercurochrome Reparador e Protetor. The expected benefit to the use of the product is the improvement in skin hydration as measured by self perception of participant research and clinical evaluation and improvement in local microcirculation, assessed by instrumental measurements in feet of the study participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objectives of this study is to verify the skin acceptability through the non-occurrence of adverse events and cutaneous sensations of discomfort, evaluate the moisturizing efficacy of the product through self perception of research participants and dermatological clinical evaluation to assess the improvement in local microcirculation by performing of instrumental measurements in the feet of diabetic participants, product Laboratoires Mercurochrome Repairer and Protector referred by LM FARMA INDUSTRIAL LTDA.

For this research, will be recruited up to 35 research participants who meet the inclusion / exclusion described in items 9.4 and 9.5 of the research protocol, to achieve a number of completion of 30 participants. Be recruited participants from both sexes, aged 18 and 65, which have dry skin on the feet and they are people with diabetes whose condition is stabilized.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Laboratoires Mercurochrome Reparador

A group of patients will be treated with a new restorative skin cream consists of hyperoxygenation essential fatty acids (60% linoleic acid) which does not contain preservatives (parabens) or known allergens.

Group Type EXPERIMENTAL

Laboratoires Mercurochrome Reparador

Intervention Type DEVICE

Developed for the treatment of damaged or fragile skin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laboratoires Mercurochrome Reparador

Developed for the treatment of damaged or fragile skin.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Urgo Repair

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants healthy research;
* Intact skin on feet - grade 0 in the Wagner scale;
* Agreement to adhere to the procedures and requirements of the study and attend to the Office (s) day (s) and time (s) set (s) for evaluations;
* Ability to consent to participate in writing;
* Age 18 to 65 years;
* Research Participants of both sexes - including at least three men;
* Introducing dry skin on feet - dermatological proof.
* Participants with diabetes whose condition is stabilized

Exclusion Criteria

* Pregnancy and lactation; skin pathology in the product application area;
* immune impairment;
* Current use of these medications for topical or systemic use: corticoid, immunosuppressants, antihistamines, anticoagulants or birth;
* Skin diseases: psoriasis, vitiligo, atopic dermatitis;
* History of reaction to the category of the product tested;
* Other diseases or medications that may interfere directly in the study or to endanger the health of the research participant.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

LM Farma Indústria e Comércio Ltda.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alexandre Tepas, Graduated

Role: STUDY_DIRECTOR

Urgo

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nesser C Oliveira, Graduated

Role: CONTACT

551230021316

Sheila M Vieira, Graduated

Role: CONTACT

551232021316

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LM Farma

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Topic Insulin Accelerates Wound Healing in Diabetes
NCT01295177 COMPLETED PHASE1/PHASE2